ERBB2 and breast cancer: One possible explanation for this finding is that HER2-nonamplified BC is a heterogeneous disease, adding individual genomic data to HER2-low expression cohort might provide additional information to identify patients at high risk, which has been confirmed in Mutai R. et al's study [29].